Evercore ISI analyst Joshua Schimmer raised the firm’s price target on TG Therapeutics (TGTX) to $25 from $16 and keeps an Outperform rating on the shares. The firm checked in with some high-prescribing neurologists following Briumvi’s approval for MS and came away with a greater appreciation of nuances that position Briumvi for "meaningful share gains" versus Roche’s Ocrevus, making it "significantly more bullish" about TG Therapeutics shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TGTX:
- TG Therapeutics call volume above normal and directionally bullish
- TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- TG Therapeutics price target raised to $23 from $19 at Jefferies
- TG Therapeutics price target raised to $16 from $11 at Evercore ISI
- Another Big Day for TGTX